Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Eikon Therapeutics, Inc. ( (EIKN) ) just unveiled an update.
On February 6, 2026, Eikon Therapeutics, Inc. completed its initial public offering of common stock and, in connection with the transaction, filed an amended and restated certificate of incorporation with the Secretary of State of Delaware, which had been approved in advance by its board of directors and stockholders to take effect immediately prior to the IPO’s closing. Effective the same date, the company also adopted amended and restated bylaws, likewise pre-approved by the board and stockholders, underscoring a comprehensive update to its corporate governance framework as it transitions to life as a publicly traded company, with implications for how it is managed and overseen going forward.
More about Eikon Therapeutics, Inc.
Eikon Therapeutics, Inc. is a biotechnology company that has recently entered the public markets through an initial public offering (IPO) of its common stock, positioning itself within the life sciences industry as a newly listed issuer subject to U.S. corporate and securities regulation.
Average Trading Volume: 4,900,769
Find detailed analytics on EIKN stock on TipRanks’ Stock Analysis page.